Drug intelligence / Profile preview

CRISPR-Cas12b

Development stage
Preclinical
Lead developer
Beam Therapeutics
Modality
CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
Administration
Electroporation (for Ribonucleoproteins), Viral Vector Delivery, Ex Vivo Delivery
01

Overview

CRISPR-Cas12b is a genome editing enzyme and a member of the type V-B CRISPR-Cas system family. It is a dual-RNA-guided endonuclease that functions as a programmable nuclease for targeted DNA editing[3][5]. **Mechanism of action:** Cas12b recognizes and cleaves target DNA sequences guided by crRNA (CRISPR RNA) and tracrRNA components. The enzyme generates double-strand breaks with 6-8 nucleotide 5' sticky ends, which are the longest sticky ends among current CRISPR-Cas systems, promoting non-homologous end joining (NHEJ)-based gene modifications[6]. Cas12b recognizes distal T-rich protospacer adjacent motifs (PAMs), primarily ATTN sequences[5]. **Key advantages:** - Smaller protein size (1,108 amino acids) compared to Cas9 (1,368 amino acids) and Cas12a (1,307 amino acids), making it suitable for viral vector delivery[7] - Higher target specificity and minimal off-target effects compared to Cas9[4][5] - Highly sensitive to mismatches—a single nucleotide mutation in the first 18 nucleotides of the target sequence is sufficient to prevent cleavage[6] - Generates larger deletions (5-15 bp) than other CRISPR systems[5] - Wide temperature and pH stability[4] - Improved stability in human plasma[4]

Other names
Type V-B CRISPR systemBhCas12b (Bacillus hisashii variant)AaCas12b (Alicyclobacillus acidoterrestris variant)
02

Targets

DNACas12

Beyond the preview

Go deeper on CRISPR-Cas12b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRISPR-Cas12b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call